SG11202100137TA - PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 - Google Patents
PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8Info
- Publication number
- SG11202100137TA SG11202100137TA SG11202100137TA SG11202100137TA SG11202100137TA SG 11202100137T A SG11202100137T A SG 11202100137TA SG 11202100137T A SG11202100137T A SG 11202100137TA SG 11202100137T A SG11202100137T A SG 11202100137TA SG 11202100137T A SG11202100137T A SG 11202100137TA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibiting
- pyridazine compounds
- pyridazine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695510P | 2018-07-09 | 2018-07-09 | |
| PCT/US2019/041026 WO2020014243A1 (en) | 2018-07-09 | 2019-07-09 | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100137TA true SG11202100137TA (en) | 2021-02-25 |
Family
ID=69143022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100137TA SG11202100137TA (en) | 2018-07-09 | 2019-07-09 | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3820860A4 (de) |
| JP (1) | JP2021531256A (de) |
| KR (1) | KR20210019119A (de) |
| CN (1) | CN112689629B (de) |
| AU (1) | AU2019302534A1 (de) |
| CA (1) | CA3105748A1 (de) |
| SG (1) | SG11202100137TA (de) |
| WO (1) | WO2020014243A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| KR20220124176A (ko) | 2019-12-06 | 2022-09-13 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 치환된 테트라하이드로푸란 |
| CN117813302A (zh) | 2021-06-04 | 2024-04-02 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂 |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| AU2022286511A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| AU2022284952A1 (en) | 2021-06-04 | 2023-12-14 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| EP4347584A1 (de) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl(hetero)aryl)tetrahydrofurancarboxamid-analoga als modulatoren von natriumkanälen |
| AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE163412T1 (de) * | 1993-06-08 | 1998-03-15 | Sanofi Sa | Pyridazine als interleukin-1-beta verwandlungsenzym inhibitoren |
| CA2741649A1 (en) * | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| CA2813704A1 (en) * | 2010-10-05 | 2012-04-12 | Purdue Pharma L.P. | Quinazoline compounds as sodium channel blockers |
| WO2013109521A1 (en) * | 2012-01-16 | 2013-07-25 | Vertex Pharmaceuticals Incorporated | Pyran-spirocyclic piperidine amides as modulators of ion channels |
| AU2013334663A1 (en) * | 2012-10-26 | 2015-05-07 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
| WO2014151393A2 (en) * | 2013-03-15 | 2014-09-25 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| PL3580220T3 (pl) * | 2017-02-13 | 2022-02-07 | Bristol-Myers Squibb Company | Aminotriazolopirydyny jako inhibitory kinaz |
-
2019
- 2019-07-09 SG SG11202100137TA patent/SG11202100137TA/en unknown
- 2019-07-09 JP JP2021500459A patent/JP2021531256A/ja active Pending
- 2019-07-09 AU AU2019302534A patent/AU2019302534A1/en active Pending
- 2019-07-09 WO PCT/US2019/041026 patent/WO2020014243A1/en unknown
- 2019-07-09 CA CA3105748A patent/CA3105748A1/en active Pending
- 2019-07-09 KR KR1020217003942A patent/KR20210019119A/ko unknown
- 2019-07-09 EP EP19833110.0A patent/EP3820860A4/de active Pending
- 2019-07-09 CN CN201980058833.4A patent/CN112689629B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3820860A1 (de) | 2021-05-19 |
| US20210139456A1 (en) | 2021-05-13 |
| CA3105748A1 (en) | 2020-01-16 |
| CN112689629B (zh) | 2024-04-23 |
| JP2021531256A (ja) | 2021-11-18 |
| AU2019302534A1 (en) | 2021-01-28 |
| CN112689629A (zh) | 2021-04-20 |
| KR20210019119A (ko) | 2021-02-19 |
| EP3820860A4 (de) | 2022-04-20 |
| WO2020014243A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202100137TA (en) | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 | |
| IL282468A (en) | 2-Amino-n-heteroaryl-nicotinamides as inhibitors of nav1.8 | |
| SG11202100130QA (en) | Pyridine carboxamide compounds for inhibiting nav1.8 | |
| IL288236A (en) | 3,2-dihydroquinazoline compounds as inhibitors of nav1.8 | |
| EP3873468A4 (de) | 2-amino-n-phenyl-nicotinamide als nav1.8-inhibitoren | |
| IL283853A (en) | Novel crispr-cas systems for genome editing | |
| IL289290A (en) | Substituted benzyltriazole compounds for cbl-b inhibition, and other uses thereof | |
| EP3583507A4 (de) | Blockkettenbasierte zulassungsverfahren für geschützte instanzen | |
| EP3578555A4 (de) | Diphenylaminopyrimidinverbindung zur hemmung der kinaseaktivität | |
| HUE061331T2 (hu) | Mutáns IDH-1 gátlása | |
| GB201806660D0 (en) | Improved secondary locking mechanism | |
| GB201810965D0 (en) | Phosphoantigen prodrug compounds | |
| PT3589637T (pt) | Compostos úteis para inibir ror-gamma-t | |
| IL279709A (en) | ASK1 inhibitory agents | |
| EP4028708C0 (de) | Schlosssystem | |
| EP3820847A4 (de) | Verbesserte verbindungen zur myc-hemmung | |
| GB2576589B (en) | Lock mechanism | |
| GB201814067D0 (en) | Compounds for the inhibition of cyclophilins | |
| GB2572742B (en) | Locking mechanism | |
| RS61788B1 (sr) | Jedinjenja korisna za inhibiciju rorγt | |
| LT3720442T (lt) | Mutantinės idh-1 slopinimas | |
| PT3710446T (pt) | Compostos úteis para inibir cdk7 | |
| GB2575636B (en) | Lock mechanism | |
| GB201819687D0 (en) | Mrbr.5 | |
| PL3521198T3 (pl) | Mechanizm zamykający |